Moderna Inc
MRNA27.215USD
-0.390-1.41%
Horário de mercado （ET）Cotações atrasadas em 15 min
10.59BValor de mercado
PerdaP/L TTM
Mais detalhes de Moderna Inc Empresa
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Informações da empresa
Código da empresaMRNA
Nome da EmpresaModerna Inc
Data de listagemDec 07, 2018
CEOMr. Stephane Bancel
Número de funcionários5800
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço325 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone16177146500
Sitehttps://www.modernatx.com/
Código da empresaMRNA
Data de listagemDec 07, 2018
CEOMr. Stephane Bancel
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Por RegiãoUSD
Nome
Receita
Proporção
Rest of the World
55.00M
63.95%
United States
31.00M
36.05%
Europe
0.00
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Tipos de investidores
Investidores
Proporção
Investment Advisor
40.95%
Investment Advisor/Hedge Fund
14.84%
Hedge Fund
7.44%
Corporation
4.68%
Research Firm
4.41%
Individual Investor
2.56%
Bank and Trust
2.41%
Pension Fund
1.26%
Venture Capital
1.21%
Other
20.25%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
2012
312.35M
80.76%
-23.80M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
40.25M
10.41%
+71.93K
+0.18%
Mar 31, 2025
Baillie Gifford & Co.
24.95M
6.45%
-13.94M
-35.85%
Mar 31, 2025
Fidelity Management & Research Company LLC
20.83M
5.39%
+2.44M
+13.30%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.87M
4.62%
-166.51K
-0.92%
Mar 31, 2025
State Street Global Advisors (US)
17.78M
4.6%
+201.32K
+1.15%
Mar 31, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Two Sigma Investments, LP
8.26M
2.14%
+7.49M
+976.22%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.46M
1.93%
+215.24K
+2.97%
Mar 31, 2025
Theleme Partners LLP
7.24M
1.87%
-64.47K
-0.88%
Mar 31, 2025
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
4.09%
Global X Genomics & Biotechnology ETF
4.08%
First Trust NYSE Arca Biotechnology Index Fund
3.31%
SPDR S&P Biotech ETF
2.42%
VanEck Biotech ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.94%
Langar Global HealthTech ETF
1.9%
WisdomTree BioRevolution Fund
1.66%
Invesco S&P 500 Equal Weight Health Care ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.43%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção4.09%
Global X Genomics & Biotechnology ETF
Proporção4.08%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.31%
SPDR S&P Biotech ETF
Proporção2.42%
VanEck Biotech ETF
Proporção2.35%
Virtus LifeSci Biotech Products ETF
Proporção1.94%
Langar Global HealthTech ETF
Proporção1.9%
WisdomTree BioRevolution Fund
Proporção1.66%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.65%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.43%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
